PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cefamandole Nafate→

Cefamandole Nafate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
42540-40-9
Molecular formula
C19H17N6NaO6S2
Molecular weight
512.5 g/mol
Drug class
Second-generation cephalosporin beta-lactam antibacterial (cefamandole prodrug salt)
Mechanism of action
Cefamandole binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall cross-linking, producing bactericidal activity against susceptible organisms. Nafate is the formulation/salt form and does not create a different antibacterial target.
Indications / reported uses
  • Historically used for infections caused by cefamandole-susceptible bacteria, including selected respiratory, urinary, skin/soft-tissue, bone/joint and intra-abdominal infections; availability is limited and current use is jurisdiction-specific

Sources: NLM MeSH — Cefamandole · PubMed — Cefamandole clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cefamandole Nafate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cefamandole Nafate Permitted Daily Exposure (PDE) report (the Cefamandole Nafate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cefamandole Nafate Occupational Exposure Limit (OEL) report (the Cefamandole Nafate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.